Canaccord Genuity Group Issues Positive Forecast for Repligen (NASDAQ:RGEN) Stock Price

Key Points

• Canaccord Genuity Group raised Repligen’s price target from $145 to $180 but maintained a “hold” rating, implying approximately 2.6% upside from the reported share price.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $175.71; targets from other firms range as high as $225.
• Repligen exceeded quarterly earnings and revenue expectations, reporting $0.54 in EPS and $204.13 million in revenue, while institutional investors and hedge funds own 97.64% of the stock.

Repligen (NASDAQ:RGEN - Get Free Report) had its target price increased by equities research analysts at Canaccord Genuity Group from $145.00 to $180.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has a "hold" rating on the biotechnology company's stock. Canaccord Genuity Group's target price would indicate a potential upside of 2.61% from the company's current price.

A number of other research firms also recently issued reports on RGEN. Barclays raised their price target on Repligen from $175.00 to $225.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. Evercore reissued an "outperform" rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Zacks Research downgraded shares of Repligen from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Finally, Wells Fargo & Company increased their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.71.

Repligen Stock Performance

NASDAQ RGEN opened at $175.42 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm's fifty day moving average price is $175.86 and its 200 day moving average price is $145.75. The company has a market capitalization of $9.90 billion, a price-to-earnings ratio of 240.30, a price-to-earnings-growth ratio of 3.20 and a beta of 1.08. Repligen has a 12 month low of $100.99 and a 12 month high of $198.87.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the business earned $0.26 EPS. Repligen's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts expect that Repligen will post 2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the 2nd quarter valued at approximately $52,000. CoreCap Advisors LLC boosted its stake in shares of Repligen by 1,275.0% during the 3rd quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 255 shares in the last quarter. Harbor Investment Advisory LLC boosted its stake in shares of Repligen by 198.9% during the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 348 shares in the last quarter. Trust Co. of Vermont acquired a new stake in shares of Repligen in the 2nd quarter worth approximately $71,000. Finally, Allworth Financial LP acquired a new stake in shares of Repligen in the 2nd quarter worth approximately $71,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.